<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> are characterized by ineffective hematopoiesis resulting in peripheral cytopenias </plain></SENT>
<SENT sid="1" pm="."><plain>The majority of patients is dependent on regular transfusions of packed red blood cells leading to a secondary <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> which might result in organ damage </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, sufficient iron chelation therapy in selected patients is mandatory </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> (DFX) is an orally administered iron <z:chebi fb="0" ids="38161">chelator</z:chebi> which has been highly efficient in the treatment of secondary <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Most frequent side effects of DFX are gastrointestinal disturbances, which leads in some patients to low adherence to the therapy </plain></SENT>
<SENT sid="5" pm="."><plain>An expert panel met in Lisbon in July 2010 to develop recommendations on prevention and management of GI disturbances based on existing data and personal experiences </plain></SENT>
</text></document>